PharmaCyte Biotech, Inc. Common Stock (PMCB) Stock Price

PMCBStock

$0.54−45.88%52W

Market Cap$5.79M

P/E0.20x

PEG Ratio—

Div yield—

Beta0.67

PMCB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-31.34%

Price vs S&P 500 (4W)-14.07%

VGM Score26.27

P/E Ratio (Annual)0.20x

Book Value / Share (Quarterly)$3.26

P/TBV (Annual)0.22x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.48

Price vs S&P 500 (YTD)-39.45%

Gross Margin (TTM)81.70%

Net Profit Margin (TTM)-4184.21%

EPS (TTM)$-2.65

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-2.65

EPS (Annual)$-2.32

ROI (Annual)-55.53%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-4635.63%

Cash / Share (Quarterly)$3.45

P/E Normalized (Annual)0.20x

ROA (Last FY)-41.55%

EBITD / Share (TTM)$-0.81

ROE (5Y Avg)-1.25%

Operating Margin (TTM)-3469.42%

Cash Flow / Share (Annual)$-0.48

P/B Ratio0.17x

P/B Ratio (Quarterly)0.22x

Net Income / Employee (Annual)$-9,712,300

EV / Revenue (TTM)-318.28x

Net Interest Coverage (TTM)-4.34x

ROA (TTM)-38.14%

EV / EBITDA (TTM)-6.47x

EPS Incl Extra (Annual)$-2.32

Current Ratio (Annual)45.28x

Quick Ratio (Quarterly)45.16x

3-Month Avg Trading Volume0.16M

52-Week Price Return-45.88%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.26

P/S Ratio (Annual)590.46x

Asset Turnover (Annual)0.00x

52-Week High$1.51

Operating Margin (5Y Avg)-4103.67%

EPS Excl Extra (Annual)$-2.32

Tangible BV CAGR (5Y)62.05%

26-Week Price Return-20.09%

Quick Ratio (Annual)45.16x

13-Week Price Return-34.05%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)45.28x

Enterprise Value$-12.70M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-4.96%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.33x

Pretax Margin (Annual)-16000.00%

Cash / Share (Annual)$3.45

3-Month Return Std Dev59.17%

Gross Margin (5Y Avg)37.52%

Net Income / Employee (TTM)$-9,712,300

ROE (Last FY)-55.53%

Net Interest Coverage (Annual)-1.23x

EPS Basic Excl Extra (Annual)$-2.32

Receivables Turnover (TTM)1.96x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.65

Receivables Turnover (Annual)26.00x

ROI (TTM)-50.28%

P/S Ratio (TTM)147.99x

Pretax Margin (5Y Avg)-4635.63%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.26

Price vs S&P 500 (52W)-64.19%

Year-to-Date Return-27.49%

5-Day Price Return0.17%

EPS Normalized (Annual)$-2.32

ROA (5Y Avg)0.80%

Net Profit Margin (Annual)-16000.00%

Month-to-Date Return-8.85%

Cash Flow / Share (TTM)$-0.21

EBITD / Share (Annual)$-0.81

Operating Margin (Annual)-14500.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-1.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.65

P/TBV (Quarterly)0.22x

P/B Ratio (Annual)0.22x

Inventory Turnover (TTM)5.10x

Pretax Margin (TTM)-4184.21%

Book Value / Share (Annual)$3.26

Price vs S&P 500 (13W)-36.85%

Beta0.67x

Revenue / Share (TTM)$0.00

ROE (TTM)-50.28%

52-Week Low$0.50

mGradeD

vgmGradeD

PMCB Earnings Surprise History

Q3 21-0.06est. -0.07

Q4 21-0.04est. -0.05

Q1 22-0.06est. -0.04

Q2 22-0.07est. -0.07

PMCB Analyst Recommendations

Nov 2022

Dec 2022

Jan 2023

Feb 2023

2.17

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
PMCBPharmaCyte Biotech, Inc. Common Stock	—	—	D	$0.54
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About PharmaCyte Biotech, Inc. Common Stock

PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology, which encapsulates live cells to deliver cancer-killing drugs directly at tumor sites. The platform is designed to protect therapeutic cells from the immune system while enabling localized drug delivery, with current development efforts focused on inoperable pancreatic cancer and other solid tumors. The company is leveraging this platform technology to address multiple cancer indications and diabetes.